Hydroxyurea for children with sickle cell disease
Hydroxyurea therapy offers promise for ameliorating the clinical course of children with sickle cell disease (SCD). Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal side effects, has a relatively wide therapeutic window, and has mechanisms of action that address pa...
Saved in:
Published in | Hematology/oncology clinics of North America Vol. 24; no. 1; p. 199 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
01.02.2010
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | Hydroxyurea therapy offers promise for ameliorating the clinical course of children with sickle cell disease (SCD). Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal side effects, has a relatively wide therapeutic window, and has mechanisms of action that address pathophysiologic pathways of sickling, vaso-occlusion, hemolysis, and organ damage. There are limited data regarding hydroxyurea's ability to prevent or diminish organ dysfunction, and the long-term risks of hydroxyurea therapy remain incompletely defined. Although clinical trials are underway to address long-term issues, hydroxyurea remains an effective but underutilized therapy for SCD. |
---|---|
ISSN: | 1558-1977 |
DOI: | 10.1016/j.hoc.2009.11.002 |